Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · IEX Real-Time Price · USD

51.30

-0.72 (-1.38%)

At close: Jul 2, 2024, 4:00 PM

51.29

-0.01 (-0.02%)

After-hours: Jul 2, 2024, 5:50 PM EDT

Halozyme Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2001
Net Income	281.59	202.13	402.71	129.09	-72.24	Upgrade
Depreciation & Amortization	84.86	49.64	3	3.28	4.07	Upgrade
Share-Based Compensation	36.62	24.4	20.82	17.2	34.78	Upgrade
Other Operating Activities	-14.5	-36.06	-127.09	-94.12	-52.03	Upgrade
Operating Cash Flow	388.57	240.11	299.44	55.45	-85.42	Upgrade
Operating Cash Flow Growth	61.83%	-19.81%	439.98%	-	-	Upgrade
Capital Expenditures	-15.29	21.2	-1.46	-1.43	-4.04	Upgrade
Acquisitions	0	-999.12	0	0	0	Upgrade
Change in Investments	-81.62	490.92	-404.83	79.78	-1.51	Upgrade
Investing Cash Flow	-96.91	-487.01	-406.29	78.35	-5.55	Upgrade
Share Issuance / Repurchase	-394.5	-185.95	-337.52	-86.72	-185.77	Upgrade
Debt Issued / Paid	-13.48	617.44	415.39	-19.56	338.99	Upgrade
Other Financing Activities	-	-69.12	-	-	-	Upgrade
Financing Cash Flow	-407.99	362.37	77.87	-106.28	153.22	Upgrade
Net Cash Flow	-116.33	115.48	-28.98	27.52	62.24	Upgrade
Free Cash Flow	373.28	261.31	297.98	54.03	-89.46	Upgrade
Free Cash Flow Growth	42.85%	-12.31%	451.55%	-	-	Upgrade
Free Cash Flow Margin	45.01%	39.58%	67.22%	20.19%	-45.65%	Upgrade
Free Cash Flow Per Share	2.83	1.91	2.12	0.40	-0.62	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).